Söndag 4 Maj | 06:54:11 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-27 08:30 Kvartalsrapport 2025-Q3
2025-08-28 08:30 Kvartalsrapport 2025-Q2
2025-05-28 N/A Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-04-23 - Extra Bolagsstämma 2025
2025-04-11 - X-dag ordinarie utdelning CURAS 0.00 DKK
2025-02-27 - Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-07-02 - Extra Bolagsstämma 2024
2024-05-23 - Kvartalsrapport 2024-Q1
2024-03-22 - X-dag ordinarie utdelning CURAS 0.00 DKK
2024-03-21 - Årsstämma
2024-02-22 - Bokslutskommuniké 2023
2023-11-23 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-03-31 - X-dag ordinarie utdelning CURAS 0.00 DKK
2023-03-30 - Årsstämma
2023-02-23 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-24 - Kvartalsrapport 2022-Q1
2022-04-27 - Årsstämma
2022-03-25 - X-dag ordinarie utdelning CURAS 0.00 DKK
2022-02-24 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-01 - Extra Bolagsstämma 2021
2021-05-20 - Kvartalsrapport 2021-Q1
2021-03-26 - X-dag ordinarie utdelning CURAS 0.00 DKK
2021-03-25 - Årsstämma
2021-02-24 - Bokslutskommuniké 2020
2020-11-30 - Kvartalsrapport 2020-Q3

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen är bred och har sin huvudsakliga fokus på utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.
2025-05-02 07:30:53

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Today is the first day of the subscription period in Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) rights issue of shares (the "Rights Issue"). On 4 April 2025, the Board of Directors resolved on its intention to carry out the Rights Issue. The Extraordinary General Meeting held on 23 April 2025 authorized the Board to carry out the Rights Issue, and the Board subsequently resolved to carry out the Rights Issue on 24 April 2025.

Summary of the Rights Issue

  • Each holder of existing shares registered with Euronext Securities as of the record date, 1 May 2025, have been allocated forty-three (43) subscription rights for each existing share held. Eighteen (18) Subscription Rights entitle the holder to subscribe for one (1) new share.
  • The subscription price is DKK 1.98 per share, and upon full subscription, Curasight will receive approximately DKK 100 million in gross proceeds through the Rights Issue before deduction of transaction costs
  • The rights issue is covered by subscription undertaking of approximately DKK 27.7 million by Curium, Pentwater, members of the Board of Directors & management and existing shareholders. In addition, the Rights issue is covered by guarantee commitments from a number of external investors, corresponding to a total of approximately DKK 19.3 million. In total, the Rights Issue is thus covered by subscription and guarantee commitments totaling approximately DKK 47 million, which corresponds to approximately 47% of the Rights Issue.
  • The subscription period begins on 2 May 2025 and ends on 16 May 2025. Trading in subscription rights began on 30 April 2025 and ends on 14 May 2025.

Disclosure document

No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document (the "Information Document") in accordance with article 1.4 db) in Regulation (EU) 2024/2809 ("Listing Act"). Further information concerning the Rights Issue and the Company is provided in the Information Document, which has been prepared in accordance with Annex IX of the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation"). The Information Document is available on the Company's website, www.curasight.com. This website also contain a link to the subscription form for subscription. 

Time plan for the Rights Issue

30 April 2025 - 14 May 2025 Trading in subscription rights
2 May 2025 - 16 May 2025 Subscription period
21 May 2025 Estimated publication of the outcome of the Rights Issue

Advisors

Sedermera Corporate Finance AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue. DLA Piper is the Company's legal advisor. Danske Bank A/S is the settlement agent.